Are These Stocks Primed for the Gutter? – Nasdaq, Inc. (NDAQ) And Rigel Pharmaceuticals, Inc. (RIGL)

7 analysts out of 15 Wall Street brokerage firms rate Nasdaq, Inc. (NASDAQ:NDAQ) as a Buy, while 0 see it as a Sell. The rest 8 describe it as a Hold. NDAQ stock traded higher to an intra-day high of $85.01. At one point in session, its potential discontinued and the price was down to lows at $83.81. Analysts have set NDAQ’s consensus price at $94, effectively giving it a 11.92% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $105 (up 25.01% from current price levels). NDAQ has a 8.2% ROE, lower than the 16.57% average for the industry. The average ROE for the sector is 16.13%.

It is expected that in Mar 2019 quarter NDAQ will have an EPS of $1.21, suggesting a -2.42% growth. For Jun 2019 is projected at $1.25. It means that there could be a 5.93% growth in the quarter. Yearly earnings are expected to rise by 5.58% to about $5.11. As for the coming year, growth will be about 8.61%, lifting earnings to $5.55. RSI after the last trading period was 40.21. NDAQ recorded a change of -2.3% over the past week and returned -3.8% over the last three months while the NDAQ stock’s monthly performance revealed a shift in price of -4.09%. The year to date (YTD) performance stands at 2.97%, and the bi-yearly performance specified an activity trend of -10.42% while the shares have moved -1.48% for the past 12 months.

Nasdaq, Inc. (NDAQ) currently trades at $83.99, which is lower by -1.25% its previous price. It has a total of 170.44 million outstanding shares, with an ATR of around 1.43. The company’s stock volume dropped to 0.84 million, worse than 897.27 thousands that represents its 50-day average. A 5-day decrease of about -2.3% in its price means NDAQ is now 2.97% higher on year-to-date. The shares had marked a $96.84 52-week high price and the 52 week low of $75.49. Overall, it has seen a growth rate of -1.48 over the last 12 months.

Nasdaq, Inc. (NASDAQ:NDAQ)’s EPS was $1.26 as reported for the December quarter. In comparison, the same quarter a year ago had an EPS of $1.05. That means that its growth in general now stands at 20%. Therefore, a prediction of $1.27 given by the analysts brought a negative surprise of -1%. NDAQ Dec 19 quarter revenue was $645 million, compared to $635 million recorded in same quarter last year, giving it a 2% growth rate. The company’s $10 million revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares depreciated -1.71% over the last trading period, taking overall 5-day performance up to 3.6%. RIGL’s price now at $2.3 is greater than the 50-day average of $2.24. Getting the trading period increased to 200 days, the stock price was seen at $2.79 on average. The general public currently hold control of a total of 166.75 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 171.01 million. The company’s management holds a total of 0.1%, while institutional investors hold about 97.6% of the remaining shares. RIGL share price finished last trade 0.66% above its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -17.67%, while closing the session with 2.85% distance from 50 day simple moving average.

Rigel Pharmaceuticals, Inc. (RIGL) shares were last observed trading -50.85% down the peak of $4.68. Last month’s price growth of 2.22% puts RIGL performance for the year now at 0%. Consequently, the shares price is trending higher by 17.35%, a 52-week worst price. However, it is losing value with -28.13% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $2.23 and $2.26. The immediate resistance area is now $2.35 Williams’s %R (14) for RIGL moved to 31.82 while the stochastic %K points at 73.48.